How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
36
COGT Quote, Financials, Valuation and Earnings
Last price:
$37.04
Seasonality move
:
-20%
Day range:
$36.11 - $37.39
52-week range:
$3.72 - $43.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
55.99x
P/B ratio:
29.26x
Volume:
1.8M
Avg. volume:
2.2M
1-year change:
304.36%
Market cap:
$5.7B
Revenue:
--
EPS (TTM):
-$2.37
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
COGT
Cogent Biosciences, Inc.
|
-- | -$0.51 | -- | -4.86% | $50.75 |
|
CDTX
Cidara Therapeutics, Inc.
|
-- | -$1.56 | -100% | -71.03% | $221.50 |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$155.3M | -$1.25 | 45.76% | -35.54% | $90.67 |
|
OLMA
Olema Pharmaceuticals, Inc.
|
-- | -$0.53 | -- | -50.05% | $45.90 |
|
PFE
Pfizer Inc.
|
$16.8B | $0.57 | 1.36% | 40.11% | $28.71 |
|
SRPT
Sarepta Therapeutics, Inc.
|
$391M | -$0.77 | -49.33% | -91.57% | $21.43 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
COGT
Cogent Biosciences, Inc.
|
$37.08 | $50.75 | $5.7B | -- | $0.00 | 0% | 55.99x |
|
CDTX
Cidara Therapeutics, Inc.
|
$221.38 | $221.50 | $7B | -- | $0.00 | 0% | 55.23x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$86.50 | $90.67 | $14B | -- | $0.00 | 0% | 14.73x |
|
OLMA
Olema Pharmaceuticals, Inc.
|
$25.36 | $45.90 | $1.7B | -- | $0.00 | 0% | -- |
|
PFE
Pfizer Inc.
|
$27.22 | $28.71 | $154.8B | 20.09x | $0.43 | 6.32% | 2.48x |
|
SRPT
Sarepta Therapeutics, Inc.
|
$18.50 | $21.43 | $1.9B | 20.50x | $0.00 | 0% | 0.79x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
COGT
Cogent Biosciences, Inc.
|
16.68% | 3.084 | 2.86% | 6.28x |
|
CDTX
Cidara Therapeutics, Inc.
|
0.47% | 5.000 | 0.07% | 4.47x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
76.83% | 2.779 | 19.43% | 2.51x |
|
OLMA
Olema Pharmaceuticals, Inc.
|
1.44% | 0.190 | 0.67% | 7.90x |
|
PFE
Pfizer Inc.
|
39.94% | 0.402 | -- | 0.81x |
|
SRPT
Sarepta Therapeutics, Inc.
|
48.64% | -0.463 | 61.92% | 1.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
COGT
Cogent Biosciences, Inc.
|
-$1.1M | -$83.4M | -103.58% | -117.99% | -- | -$64.4M |
|
CDTX
Cidara Therapeutics, Inc.
|
-$28K | -$43.6M | -68.01% | -68.74% | -3675.83% | -$40.6M |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$151.5M | -$160.2M | -9.92% | -43.01% | -102.21% | -$138.4M |
|
OLMA
Olema Pharmaceuticals, Inc.
|
-$43K | -$45.9M | -45.23% | -45.61% | -- | -$34.5M |
|
PFE
Pfizer Inc.
|
$12.3B | $3.7B | 5.07% | 10.84% | 21.01% | $4B |
|
SRPT
Sarepta Therapeutics, Inc.
|
$230.1M | -$62.9M | -10.24% | -20.67% | -15.75% | -$55.6M |
Cogent Biosciences, Inc. vs. Competitors
-
Which has Higher Returns COGT or CDTX?
Cidara Therapeutics, Inc. has a net margin of -- compared to Cogent Biosciences, Inc.'s net margin of -30201.66%. Cogent Biosciences, Inc.'s return on equity of -117.99% beat Cidara Therapeutics, Inc.'s return on equity of -68.74%.
Company Gross Margin Earnings Per Share Invested Capital COGTCogent Biosciences, Inc.-- -$0.59 $363M CDTXCidara Therapeutics, Inc.81.53% -$3.10 $424.4M -
What do Analysts Say About COGT or CDTX?
Cogent Biosciences, Inc. has a consensus price target of $50.75, signalling upside risk potential of 36.87%. On the other hand Cidara Therapeutics, Inc. has an analysts' consensus of $221.50 which suggests that it could grow by 0.05%. Given that Cogent Biosciences, Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Cogent Biosciences, Inc. is more attractive than Cidara Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings COGTCogent Biosciences, Inc.9 2 0 CDTXCidara Therapeutics, Inc.0 3 0 -
Is COGT or CDTX More Risky?
Cogent Biosciences, Inc. has a beta of 0.451, which suggesting that the stock is 54.923% less volatile than S&P 500. In comparison Cidara Therapeutics, Inc. has a beta of 1.561, suggesting its more volatile than the S&P 500 by 56.074%.
-
Which is a Better Dividend Stock COGT or CDTX?
Cogent Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cidara Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cogent Biosciences, Inc. pays -- of its earnings as a dividend. Cidara Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios COGT or CDTX?
Cogent Biosciences, Inc. quarterly revenues are --, which are smaller than Cidara Therapeutics, Inc. quarterly revenues of --. Cogent Biosciences, Inc.'s net income of -$80.9M is higher than Cidara Therapeutics, Inc.'s net income of -$83.2M. Notably, Cogent Biosciences, Inc.'s price-to-earnings ratio is -- while Cidara Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cogent Biosciences, Inc. is 55.99x versus 55.23x for Cidara Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COGTCogent Biosciences, Inc.55.99x -- -- -$80.9M CDTXCidara Therapeutics, Inc.55.23x -- -- -$83.2M
-
Which has Higher Returns COGT or IONS?
Ionis Pharmaceuticals, Inc. has a net margin of -- compared to Cogent Biosciences, Inc.'s net margin of -82.06%. Cogent Biosciences, Inc.'s return on equity of -117.99% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.
Company Gross Margin Earnings Per Share Invested Capital COGTCogent Biosciences, Inc.-- -$0.59 $363M IONSIonis Pharmaceuticals, Inc.96.67% -$0.81 $2.7B -
What do Analysts Say About COGT or IONS?
Cogent Biosciences, Inc. has a consensus price target of $50.75, signalling upside risk potential of 36.87%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $90.67 which suggests that it could grow by 4.82%. Given that Cogent Biosciences, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Cogent Biosciences, Inc. is more attractive than Ionis Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings COGTCogent Biosciences, Inc.9 2 0 IONSIonis Pharmaceuticals, Inc.10 6 0 -
Is COGT or IONS More Risky?
Cogent Biosciences, Inc. has a beta of 0.451, which suggesting that the stock is 54.923% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.94%.
-
Which is a Better Dividend Stock COGT or IONS?
Cogent Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cogent Biosciences, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios COGT or IONS?
Cogent Biosciences, Inc. quarterly revenues are --, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Cogent Biosciences, Inc.'s net income of -$80.9M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Cogent Biosciences, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cogent Biosciences, Inc. is 55.99x versus 14.73x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COGTCogent Biosciences, Inc.55.99x -- -- -$80.9M IONSIonis Pharmaceuticals, Inc.14.73x -- $156.7M -$128.6M
-
Which has Higher Returns COGT or OLMA?
Olema Pharmaceuticals, Inc. has a net margin of -- compared to Cogent Biosciences, Inc.'s net margin of --. Cogent Biosciences, Inc.'s return on equity of -117.99% beat Olema Pharmaceuticals, Inc.'s return on equity of -45.61%.
Company Gross Margin Earnings Per Share Invested Capital COGTCogent Biosciences, Inc.-- -$0.59 $363M OLMAOlema Pharmaceuticals, Inc.-- -$0.49 $312M -
What do Analysts Say About COGT or OLMA?
Cogent Biosciences, Inc. has a consensus price target of $50.75, signalling upside risk potential of 36.87%. On the other hand Olema Pharmaceuticals, Inc. has an analysts' consensus of $45.90 which suggests that it could grow by 80.99%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than Cogent Biosciences, Inc., analysts believe Olema Pharmaceuticals, Inc. is more attractive than Cogent Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings COGTCogent Biosciences, Inc.9 2 0 OLMAOlema Pharmaceuticals, Inc.9 0 0 -
Is COGT or OLMA More Risky?
Cogent Biosciences, Inc. has a beta of 0.451, which suggesting that the stock is 54.923% less volatile than S&P 500. In comparison Olema Pharmaceuticals, Inc. has a beta of 1.895, suggesting its more volatile than the S&P 500 by 89.486%.
-
Which is a Better Dividend Stock COGT or OLMA?
Cogent Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Olema Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cogent Biosciences, Inc. pays -- of its earnings as a dividend. Olema Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios COGT or OLMA?
Cogent Biosciences, Inc. quarterly revenues are --, which are smaller than Olema Pharmaceuticals, Inc. quarterly revenues of --. Cogent Biosciences, Inc.'s net income of -$80.9M is lower than Olema Pharmaceuticals, Inc.'s net income of -$42.2M. Notably, Cogent Biosciences, Inc.'s price-to-earnings ratio is -- while Olema Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cogent Biosciences, Inc. is 55.99x versus -- for Olema Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COGTCogent Biosciences, Inc.55.99x -- -- -$80.9M OLMAOlema Pharmaceuticals, Inc.-- -- -- -$42.2M
-
Which has Higher Returns COGT or PFE?
Pfizer Inc. has a net margin of -- compared to Cogent Biosciences, Inc.'s net margin of -9.34%. Cogent Biosciences, Inc.'s return on equity of -117.99% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital COGTCogent Biosciences, Inc.-- -$0.59 $363M PFEPfizer Inc.69.97% -$0.29 $154.8B -
What do Analysts Say About COGT or PFE?
Cogent Biosciences, Inc. has a consensus price target of $50.75, signalling upside risk potential of 36.87%. On the other hand Pfizer Inc. has an analysts' consensus of $28.71 which suggests that it could grow by 5.48%. Given that Cogent Biosciences, Inc. has higher upside potential than Pfizer Inc., analysts believe Cogent Biosciences, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings COGTCogent Biosciences, Inc.9 2 0 PFEPfizer Inc.7 15 1 -
Is COGT or PFE More Risky?
Cogent Biosciences, Inc. has a beta of 0.451, which suggesting that the stock is 54.923% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.
-
Which is a Better Dividend Stock COGT or PFE?
Cogent Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.32% to investors and pays a quarterly dividend of $0.43 per share. Cogent Biosciences, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend.
-
Which has Better Financial Ratios COGT or PFE?
Cogent Biosciences, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Cogent Biosciences, Inc.'s net income of -$80.9M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Cogent Biosciences, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 20.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cogent Biosciences, Inc. is 55.99x versus 2.48x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COGTCogent Biosciences, Inc.55.99x -- -- -$80.9M PFEPfizer Inc.2.48x 20.09x $17.6B -$1.6B
-
Which has Higher Returns COGT or SRPT?
Sarepta Therapeutics, Inc. has a net margin of -- compared to Cogent Biosciences, Inc.'s net margin of -45.06%. Cogent Biosciences, Inc.'s return on equity of -117.99% beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.
Company Gross Margin Earnings Per Share Invested Capital COGTCogent Biosciences, Inc.-- -$0.59 $363M SRPTSarepta Therapeutics, Inc.57.63% -$1.80 $2.6B -
What do Analysts Say About COGT or SRPT?
Cogent Biosciences, Inc. has a consensus price target of $50.75, signalling upside risk potential of 36.87%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $21.43 which suggests that it could grow by 15.86%. Given that Cogent Biosciences, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Cogent Biosciences, Inc. is more attractive than Sarepta Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings COGTCogent Biosciences, Inc.9 2 0 SRPTSarepta Therapeutics, Inc.7 14 3 -
Is COGT or SRPT More Risky?
Cogent Biosciences, Inc. has a beta of 0.451, which suggesting that the stock is 54.923% less volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.731%.
-
Which is a Better Dividend Stock COGT or SRPT?
Cogent Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cogent Biosciences, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios COGT or SRPT?
Cogent Biosciences, Inc. quarterly revenues are --, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. Cogent Biosciences, Inc.'s net income of -$80.9M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, Cogent Biosciences, Inc.'s price-to-earnings ratio is -- while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cogent Biosciences, Inc. is 55.99x versus 0.79x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income COGTCogent Biosciences, Inc.55.99x -- -- -$80.9M SRPTSarepta Therapeutics, Inc.0.79x 20.50x $399.4M -$179.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
